Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Non-Randomized, Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety and Reactogenicity of a Single Dose of Combined Reduced-Antigen-Content Diphtheria, Tetanus and Acellular Pertussis (dTpa) Vaccine in Japanese Healthy Pregnant Women

NCT07596199 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07596199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07596199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Non-Randomized, Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety and Reactogenicity of a Single Dose of Combined Reduced-Antigen-Content Diphtheria, Tetanus and Acellular Pertussis (dTpa) Vaccine in Japanese Healthy Pregnant Women
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 29, 2026
Completion date
December 31, 2026
Enrollment
102 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria-tetanus-acellular pertussis vaccines